Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Break Below Two Hundred Day Moving Average – Here’s Why

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $14.87 and traded as low as $14.10. Ono Pharmaceutical shares last traded at $14.10, with a volume of 1,000 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Ono Pharmaceutical Stock Performance

The business’s fifty day moving average is $15.14 and its two-hundred day moving average is $14.87. The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $6.63 billion, a PE ratio of 13.43 and a beta of 0.38.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.